Page 1

Bibliometric Analysis of the FP7 High Impact Project on

Advanced Immunization Technologies November 2015

EXECUTIVE SUMMARY

A highly innovative project was launched October 1, 2011 to develop new vaccination strategies: ADITEC (Advanced Immunization Technologies). This project, funded through the 7th Framework Programme of the European Union, aims to accelerate the development of novel and powerful immunization technologies for the next generation of human vaccines. Scientists from 43 partner institutions in 13 different countries collaborate in the ADITEC project. This report presents an analysis performed by ADITEC management on publications resulting from research funded by the ADITEC project and bearing the ADITEC funding acknowledgement. The number of citations, as well as Journal Impact Factors (JIF) were used as an indicators of research quality and co-authorship as an index of collaboration. This information was gathered using Scopus and in few occasions, Publish or Perish in addition to SCImago Journal & Country Rank.

HIGH NUMBER OF ADITEC PUBLICATIONS

To date, ADITEC projects have produced 148 publications. The number of publications with an ADITEC project acknowledgement has increased each year since the beginning of the project in 2012. This trend is to be expected to continue as the project gets underway and new data becomes available.

ADITEC PUBLICATIONS ARE OF HIGH QUALITY

88 % of papers were published in journal with impact factors in Quartile 1 of their respective subject categories. The total Journal Impact Factor (JIF) of all ADITEC publications is 1010 with an average of 7.21. The highest JIF was 54.42.

Page 2

ADITEC PROJECT RESEARCH IS HIGHLY CITED

The quality of ADITEC funded research, as measured by raw number of citations, has been maintained while output has grown. The raw citation impact of ADITEC project research publications is 1645 in four years with and average number of 11.1 citations per paper.

ADITEC PROMOTES PARTNERSHIPS

Research funded through the ADITEC project is highly collaborative. About 72% of all ADITEC publications were cross-sector (for example, between academic institutions and the governmental organizations). 23% involved multiple ADITEC project partners and 69% involved multiple organizations. 30 countries were represented in author affiliations.

KEY FINDINGS FROM THE ANALYSIS

As many published articles are still quite recent, the full impact of the research is not yet identifiable. Over the next months and years as dissemination grows, the impact of this project’s research will continue to grow beyond the numbers we see today. ADITEC has published a total of 148 unique publications to date and continues to show substantial growth. Research publications/year increased between 2012 and 2015, with a 50% increase from 2012 to 2013 and then a 67% increase from ’13 to 2014. (Data on 2015 through September only.)

0

10

20

30

40

50

60

2012 2013 2014 2015

22 33

55 38

# Publications per Year

Page 3

ADITEC publications appeared in 74 different peer reviewed journals. The total Journal Impact Factor (JIF) of all ADITEC publications is 1010 with an average of 7.21.

Number of Articles Published and Title of Journals

Impact Factor

1 New England J Medicine 54.42

1 Nature 42.351

1 Nature Reviews Immunology 33.836

1 Cell 33.116

1 Nature Biotechnology 23.268

1 Nature Reviews: Microbiology 21.182

2 Immunity 19.748

3 Journal of Experimental Medicine 13.85

2 J Clinical Investigation 13.765

2 Immunological Reviews 12.909

2 Cell Host Microbe 12.194

2 Trends in Immunology 12.031

1 American Journal of Respiratory and Critical Care

Medicine 11.986

1 Nature Protocols 11.74

1 J. of Allery and Clinical Immunology 11.248

6 PNAS 9.681

2 Cold Spring Harbor Perspectives in Medicine 9.63

1 PloS Pathogens 9.127

1 Journal of Controlled Release 8.078

1 Trends in Microbiology 7.91

3 Current Opinion in Immunology 7.867

5 Science Translational Medicine 7.8

1 Current Opinion in Biotechnology 7.711

2 Seminars in Immunology 7.25

1 European Respiratory Society Monograph 7.125

1 Molecular Therapy 7.04

1 Mucosal Immunology 6.963

1 AIDS 6.557

1 Seminars in Immunopathology 6.482

1 Retrovirology 6.47

1 Arteriosclerosis, Thrombosis and Vascular Biology 6.338

1 Nanomedicine 5.824

2 J Internal Medicine 5.785

5 J Infectious Disease 5.778

1 Clinical Science 5.629

Page 4

7 Journal of Immunology 5.52

2 J Virology 5.076

2 European Journal of Immunology 4.97

2 Journal of Biological Chemistry 4.773

1 Biochimica et Biophys Acta 4.66

2 Annals of the New York Academy of Sciences 4.375

2 Expert Review of Vaccines 4.217

1 Immunology and Cell Biology 4.147

17 PloS one 4.092

2 Infection and Immunity 4.074

2 Applied and Environmental Microbiology 3.952

1 Pharmaceutical Research 3.952

2 Microbial Cell Factories 3.55

15 Vaccine 3.458

2 Immunobiology 3.205

1 Cytometry 3.066

1 Biogerontology 3.01

1 Current Opinion in Pulmonary Medicine 2.957

1 Journal of Biomedical Optics 2.945

1 Molecular Immunology 2.917

1 Lancet Respiratory Medicine 2.917

1 Genes And Immunity 2.913

2 International Journal of Tuberculosis and Lung Disease 2.731

1 BMC Microbiology 2.73

1 BMC Infectious Disease 2.56

1 Tuberculosis (Edinb) 2.54

1 Sensors 2.457

1 International Archives of Allergy and Immunology 2.433

1 Immunology Letters 2.367

1 Archives of Dermatological Research 1.902

1 J Vaccines and Vaccination 1.8

1 Protein Expression and Purification 1.695

1 Viral Immunology 1.636

1 ASMscience unknown

7 Frontiers of Immunology unknown

1 EBioMedicine unknown

Page 5

Most ADITEC papers were published in journals with impact factors in Quartile 1 of their respective subject categories.

Subject Category Quartile Counts

Quartile 1 131 88%

Quartile 2 12 7%

Quartile 3 2 1%

Quartile 4 2 1%

ADITEC papers are highly-cited, with 1645 raw citations in four years for the 148 articles published to date with an average citation per paper of 11.1. The most cited article, cited 118 times, was published in 2012 in the Journal of Experimental medicine. 54% of all ADITEC publications appeared in open access journals.

More than two-thirds (71%) of ADITEC papers were collaborative between institutions, with nearly a quarter of the published research resulting from collaborations of more than one ADITEC partner (24%). About 49% of all published research has resulted from international collaborations.

716

557

315

57

Number of Raw Citations per Year

2012

2013

2014

2015 1645

Total

Citations

Page 6

Over three-quarters (82%) of all ADITEC papers were published by researchers affiliated with more than one sector.

Scientists from 30 different countries involved in authoring papers resulting from ADITEC sponsored research. Below is a diagram identifying the country affiliations of authors represented and the number of ADITEC publications affiliated with that country.

Frequency and Distribution of ADITEC Collaborators

0 50 100 150

other

medical

govt

corp

academic

33

14

69

31

120

Author Affiliations by Sector

Page 7

Scientific Publications Resulting From ADITEC Support

1. Andersen P and Joshua S. Woodworth Tuberculosis vaccines – rethinking the current paradigm Trends in Immunology , 35 (8) 387 - 395 DOI: 10.1016/j.it.2014.04.006

2. Andersen P, Urdahl K. TB vaccines; promoting rapid and durable protection in the lung. Curr Opin Immunol. 2015 Aug;35:55-62. doi: 10.1016/j.coi.2015.06.001.

3. Andersen, P., S. H.E. Kaufmann: Novel vaccination strategies against tuberculosis. Cold Spring Harb Perspect Med4(6): a018523. (2014), doi: 10.1101/cshperspect.a018523.

4. Bardelli M, Alleri L, et al. Ex Vivo Analysis of Human Memory B Lymphocytes Specific for A and B Influenza Hemagglutinin by Polychromatic Flow-Cytometry. PLoS ONE 8(8): e70620. (2013) doi:10.1371/journal.pone.0070620.

5. Boer MC, et al. CD8+ Regulatory T Cells, and Not CD4+ T Cells, Dominate Suppressive Phenotype and Function after In Vitro Live Mycobacterium bovis-BCG Activation of Human Cells. PLoS One. 9(4) :e94192;2014 DOI:10.1371/journal.pone.0094192

6. Boer, MC., et al, CD39 is involved in mediating suppression by Mycobacterium bovis BCG-activated human CD8+CD39+ regulatory T cells European Journal of Immunology 29 MAY 2013 DOI: 10.1002/eji.20124328.

7. Boianelli A, et al A A Stochastic Model for CD4+ T Cell Proliferation and Dissemination Network in Primary Immune Response PLoS One. 2015 Aug 24;10(8):e0135787. doi: 10.1371/journal.pone.0135787

8. Bøje S, et al. A multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-g+ CMI responses protects against a genital infection in minipigs. Immunology and Cell Biology 2015 Aug 13. doi: 10.1038/icb.2015.79

9. Bonavita E,et al. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell.2015 Feb 12;160(4):700-14. doi: 10.1016/j.cell.2015.01.004.

10. Boon M., et al. Short-term high-fat diet increases macrophage markers in skeletal muscle accompanied by impaired insulin signaling in healthy male subjects. Clin Sci (Lond). 2015 Jan 1;128(2):143-51. doi: 10.1042/CS20140179.

11. Boraschi D., et al. The gracefully aging immune system. Sci Transl Med 2013;185:185ps8

12. Bottazzi B, et al .Recognition of Neisseria meningitidis by the Long Pentraxin PTX3 and Its Role as an Endogenous Adjuvant. PLoS One. 2015 Mar 18;10(3):e0120807. doi: 10.1371/journal.pone.0120807.

13. Bottazzi, B. et al. Multiplexed label-free optical biosensor for medical diagnostics. Journal of biomedical optics 19, 17006, doi:10.1117/1.JBO.19.1.017006 (2014).

14. Calabro, S, et al. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect Vaccine 16 May 2013 doi: 10.1016/j.vaccine.2013.05.007

15. Canovi, M. et al., A new surface plasmon resonance-based immunoassay for rapid, reproducible and sensitive quantification of pentraxin-3 in human plasma. Sensors (Basel). 14, 10864-75, doi: 10.3390/s140610864. 2014.

Page 8

16. Capone S, et al. Fusion of HCV Nonstructural Antigen to MHC Class II-associated Invariant Chain Enhances T-cell Responses Induced by Vectored Vaccines in Nonhuman Primates. Mol Ther.2014 May;22(5):1039-47. doi: 10.1038/mt.2014.15

17. Ciabattini A, Pettini E, and Medaglini D. CD4+ T Cell Priming as Biomarker to Study Immune Response to Preventive Vaccines Front Immunol. 2013; 4: 421. doi: 10.3389/fimmu.2013.00421

18. Ciabattini A, Prota G, Christensen D, Andersen P, Pozzi G, Medaglini D. Characterization of the antigen-specific CD4+ T cell response induced by prime-boost strategies with CAF01 and CpG adjuvants administered by the Intranasal and Subcutaneous Routes. Front Immunol. 2015 Aug 28;6:430. doi: 10.3389/fimmu.2015.00430

19. Cirelli E, et al, et al. Retinoic Acid Promotes Mucosal and Systemic Immune Responses after Mucosal Priming and Systemic Boosting in Mice. J Vaccines 6: 265. (2015) doi:10.4172/2157-7560.1000265

20. Cliff JM, et al. The human immune response to tuberculosis and its treatment: a view from the blood. Immunol Rev. 2015 Mar;264(1):88-102. doi: 10.1111/imr.12269

21. Climent N, et al Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses Vaccine. 2014 Oct 29;32(47):6266-76. doi: 10.1016/j.vaccine.2014.09.010

22. Commandeur S, et al. Clonal analysis of the T-cell response to in vivo expressed Mycobacterium tuberculosis protein Rv2034, using a CD154 expression based T-cell cloning method. PLoS One. 2014 Jun 6;9(6):e99203. doi: 10.1371/journal.pone.0099203.

23. Commandeur, S et al. The in vivo expressed Mycobacterium tuberculosis (IVE-TB) antigen Rv2034 induces CD4+ T-cells that protect against pulmonary infection in HLA-DR transgenic mice. Vaccine. 2014 Jun 17;32(29):3580-8. doi: 10.1016/j.vaccine.2014.05.005.

24. Cunha, C. et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. New Engl J Med. 370, 421-432, doi:10.1056/NEJMoa1211161 2014

25. Dadaglio G, et al and C. Leclerc. Antigen targeting to CD11b+ DCs in association with TLR4/TRIF signalling promotes strong CD8+ T cell responses. J. Immunol. 2014,193, 1787-1798 doi: 10.4049/jimmunol.1302974.

26. Daigo, K., Mantovani, A. & Bottazzi, B. The yin-yang of long pentraxin PTX3 in inflammation and immunity. Immunology letters, 2014 Sep;161(1):38-43 doi:10.1016/j.imlet.2014.04.012 2014.

27. Daleke-Schermerhorn Mh, et al. Decoration of outer membrane vesicles with multiple antigens using an autotransporter approach. Appl Environ Microbiol. 2014 Jul 18. pii: AEM.01941-14

28. De Gregorio E, Rappuoli R. From empiricism to rational design: a personal perspective of the evolution of vaccine development. Nat Rev Immunol. 14(7):505-14. doi:10.1038/nri3694.

29. de Paus RA, et al The influence of influenza virus infections on the development of tuberculosis. Tuberculosis (Edinb). 93:338-42;2013.

30. Dong, H et al. Induction of protective immunity against Mycobacterium tuberculosis by delivery of ESX antigens into airway dendritic cells. Mucosal Immunology May;6(3):522-34. , 2012 doi: 10.1038/mi.2012.92.

31. Doni A et al, Mantovani, A. Interactions of the humoral pattern recognition molecule PTX3 with the complement system. Immunobiology, 2012. Nov;217(11):1122-8. doi: 10.1016/j.imbio.2012.07.004

Page 9

32. Doni A, et al. An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode. J Exp Med. 2015 Jun 1;212(6):905-25. doi: 10.1084/jem.20141268 .

33. Dorhoi A, et al. MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment. J Clin Invest. 2013 Nov 1;123(11):4836-48.

34. Dorhoi A, et al. Reverse Translation in Tuberculosis: Neutrophils Provide Clues for Understanding Development of Active Disease. Front Immunol. 2014 Feb 5;5:36

35. Dormitzer P et al, Rappuoli, R, Structural vaccinology starts to deliver. Nature Reviews Microbiology, 2012. 10, 807-813 December 2012 doi:10.1038/nrmicro2893

36. Duque-Correa, M.A., et al Macrophage arginase-1 controls bacterial growth and pathology in hypoxic tuberculosis granulomas. Proc. Natl. Acad. Sci. USA www.pnas.org/cgi/doi/10.1073/pnas.1408839111 (2014)

37. Dutruel C et al Vaccine. TRANSVAC workshop on standardisation and harmonisation of analytical platforms for HIV, TB and malaria vaccines: 'How can big data help?'.2014 Jul 31;32(35):4365-8. doi: 10.1016/j.vaccine.2014.06.014. Epub 2014 Jun 17.

38. Elliott TOJP, et al Dysregulation of Apoptosis Is a Risk Factor for Tuberculosis Disease Progression J Infect Dis. first published online April 20, 2015 DOI:10.1093/infdis/jiv238

39. Epaulard O, et al. Macrophage- and Neutrophil-Derived TNF-α Instructs Skin Langerhans Cells To Prime Antiviral Immune Responses. J Immunol. 2014 Sep 1;193(5):2416-26. doi: 10.4049/jimmunol.1303339.

40. Farinacci, M., S. Weber, S.H.E. Kaufmann: The recombinant tuberculosis vaccine rBCG ΔureC::hly+ induces apoptotic vescicles for improved priming of CD4+ and CD8+ T cells. Vaccine, 30: 7608-7614 2012

41. Finco O. and Rappuoli R Designing Vaccines for the Twenty-First Century Society Front Immunol. 2014; 5: 12. Jan 23, 2014doi: 10.3389/fimmu.2014.00012

42. Fiorino, F., etal, Prime-boost strategies in mucosal immunization affect local IgA production and the type of Th response. Front Immunol. 2013; 4: 128 doi: 10.3389/fimmu.2013.00128

43. Galdiero MR et al. Tumor associated macrophages and neutrophils in cancer. Immunobiology. 2013 Nov;218(11):1402-10. doi: 10.1016/j.imbio.2013.06.003.

44. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013 Dec 12;39(6):1003-18. doi: 10.1016/j.immuni.2013.11.010.

45. Geluk A, et al Front Immunol. Innovative Strategies to Identify M. tuberculosis Antigens and Epitopes Using Genome-Wide Analyses. Society Front Immunol 2014 Jun 25;5:256. doi: 10.3389/fimmu.2014.00256. eCollection 2014.

46. Goeijenbier M, et al, BMC Microbiol. 2014;14:134. Activation of coagulation and tissue fibrin deposition in experimental influenza in ferrets. doi: 10.1186/1471-2180-14-134

47. Guenounou, S., et al. OMIP-016: Characterization of antigen-responsive macaque and human T-cells. Cytometry Part A, 83A:182–184. 2013 doi: 10.1002/cyto.a.22233

48. Haks MC, et al. Focused human gene expression profiling using dual-color reverse transcriptase multiplex ligation-dependent probe amplification (dcRT-MLPA). Vaccine, 2015 Vaccine. 2015 Apr 24. pii: S0264-410X(15)00518-6. doi: 10.1016/j.vaccine.2015.04.054

Page 10

49. Hell Knudsen NP, et al. New TB vaccine with high predicted population coverage and compatibility with modern diagnostics. PNAS 111(3):1097-1101, 2014.

50. Hervas-Stubbs S, et al. Conventional but not plasmacytoid dendritic cells foster the systemic virus-induced type I IFN response needed for efficient CD8 T cell priming. J Immunol. 2014 Aug 1;193(3):1151-61. doi: 10.4049/jimmunol.1301440.

51. Hjelm A, et al Autotransporter-based antigen display in bacterial ghosts. Appl Environ Microbiol. 2015 Jan; 81(2):726. doi: 10.1128/AEM.02733-14.

52. Hoang T, et al, Protein Energy Malnutrition during Vaccination Has Limited Influence on Vaccine Efficacy but Abolishes Immunity if Administered during Mycobacterium tuberculosis Infection Infection and Immunity. 83(5): 2118-26 doi: IAI.03030-14.

53. Inforzato A, et al. PTX3 as a paradigm for the interaction of pentraxins with the Complement system. Semin Immunol. 2013 Jun 6 :. doi: 10.1016/j.smim.2013.05.002.

54. Inforzato Aet al The“sweet”side of a long pentraxin:howglycosylationaffects PTX3 functions in innate immunity and inflammation. Front.Immun. 2013 . doi: 10.3389/fimmu.2012.00407

55. Jaillon S et al. Prototypic long pentraxin PTX3 is present in breast milk, spreads in tissues, and protects neonate mice from Pseudomonas aeruginosa lung infection.J Immunol. 2013 Aug 15;191(4):1873-82. doi: 10.4049/jimmunol.1201642

56. Jaillon S, et al. The long pentraxin PTX3 as a key component of humoral innate immunity and a candidate diagnostic for inflammatory diseases. Int Arch Allergy Immunol. 2014;165:165-78. doi: 10.1159/000368778. PMID: 25531094.

57. Jaillon S. etal., Neutrophils in innate and adaptive immunity, Seminars in Immunopathology July 2013, Volume 35, Issue 4, pp 377-394 DOI 10.1007/s00281-013-0374-8

58. Jaillon, S. et al. The Humoral Pattern Recognition Molecule PTX3 Is a Key Component of Innate Immunity against Urinary Tract Infection. Immunity 40, 621-632, doi:10.1016/j.immuni.2014.02.015 2014

59. Jiménez-Sánchez G, etal. Preparation and in vitro evaluation of imiquimod loaded polylactide-based micelles as potential vaccine adjuvants Pharm Res. 2015 Jan;32(1):311-20. doi: 10.1007/s11095-014-1465-5.

60. Job ER, , et al Serum Amyloid P Is a Sialylated Glycoprotein Inhibitor of Influenza A Viruses. 2013 PLoS ONE 8(3): e59623. doi:10.1371/journal.pone.0059623

61. Job, E. R. et al. A single amino acid substitution in the hemagglutinin of H3N2 subtype influenza A viruses is associated with resistance to the long pentraxin PTX3 and enhanced virulence in mice. J Immunol 192, 271-281, doi:10.4049/jimmunol.1301814 2014

62. Jong et al. A structurally informed autotransporter platform for efficient heterologous protein secretion and display. Microbial Cell Factories, 2012. Jun 18;11:85. doi: 10.1186/1475-2859-11-85

63. Jong W. et al An autotransporter display platform for the development of multivalent recombinant bacterial vector vaccines. Microb Cell Fact. 2014 Nov 25;13(1):162 doi:10.1186/s12934-014-0162-8

64. Joosten SA, Fletcher HA, Ottenhoff THM A Helicopter Perspective on TB Biomarkers: Pathway and Process Based Analysis of Gene ExpressionData Provides New Insight into TB Pathogenesis. PLoS ONE 8(9) (2013): e73230. doi:10.1371journal.pone.0073230

Page 11

65. Kakeda M, et al. Innate immune cells express IL-17A/F in acute generalized exanthematous pustulosis and generalized pustular psoriasis. Arch Dermatol Res. 2014, 306:933-8. doi: 10.1007/s00403-014-1488-0

66. Karlsen K, et al. A stable nanoparticulate DDA/MMG formulation acts synergistically with CpG ODN 1826 to enhance the CD4⁺ T-cell response. Nanomedicine 2014. 2014 Dec;9(17):2625-38. doi: 10.2217/nnm.14.197

67. Kaufmann SH Tuberculosis vaccine development at a divide. Curr Opin Pulm Med.2014 May;20(3):294-300. doi: 10.1097/MCP.0000000000000041.

68. Kaufmann SH, et al. The BCG replacement vaccine VPM1002: from drawing board to clinical trial.Expert Rev Vaccines. 2014 May;13(5):619-30. doi: 10.1586/14760584.2014.905746.

69. Kaufmann SH, et al. Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review. Lancet Respir Med. 2014 Apr;2(4):301-320. doi: 10.1016/S2213-2600(14)70033-5

70. Kaufmann SH, McElrath MJ, Lewis DJ, Del Giudice G. 2014. Challenges and responses in human vaccine development. Curr Opin Immunol. 28:18-26

71. Kaufmann, S.H.E., A. Dorhoi: Inflammation in tuberculosis: interactions, imbalances and interventions. (Special issue: Host pathogens) Curr. Opin. Immunol. 25:441–449 2013

72. Kaufmann, S.H.E.: Tuberculosis vaccine development: strength lies in tenacity. Trends Immunol. 33: 373–379 2012

73. Kaufmann, SHE and Gengenbacher, M.. Recombinant live vaccine candidates against tuberculosis. Current Opinion in Biotechnology, 2012. . Dec;23(6):900-7. doi: 10.1016/j.copbio.2012.03.007

74. Kaufmann, SHE., Tuberculosis vaccines: Time to think about the next generation. Seminars in Immunology 21 May 2013 doi.org/10.1016/j.smim.2013.04.006

75. Kinnear E, Caproni LJ, Tregoning JS+. 2015. A Comparison of Red Fluorescent Proteins to Model DNA Vaccine Expression by Whole Animal In Vivo Imaging PLoS One. 2015 Jun 19;10 (6):e0130375. doi: 10.1371/journal.pone.0130375

76. Knaul JK, etal. Lung-residing myeloid-derived suppressors display dual functionality in murine pulmonary tuberculosis.. Am J Respir Crit Care Med. 2014 Nov 1;190(9):1053-66. doi: 10.1164/rccm.201405-0828OC

77. Knezevic I, Moorthy V, Sheets R. WHO consultation on clinical evaluation of vaccines, 17-18 July 2014, WHO Headquarters, Geneva, Switzerland. Vaccine. 2015 Apr 21;33(17):1999-2003. doi: 10.1016/j.vaccine.2015.01.056

78. Knudsen NP, et alTuberculosis vaccine with high predicted population coverage and compatibility with modern diagnostics. Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1096-101. doi: 10.1073/pnas.1314973111.

79. Korsholm KS et al. Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant. Vaccine. 2014 Jun 30;32(31):3927-35. doi: 10.1016/j.vaccine.2014.05.050. Epub 2014 May 28

80. Lachmandas E The effect of hyperglycaemia on in vitro cytokine production and macrophage infection with Mycobacterium tuberculosis PLoS One. 2015 Feb 9;10(2):e0117941 doi:10.1371/journal.pone.0117941.

Page 12

81. Legaz S, et al. A purified truncated form of yeast Gal4 expressed in Escherichia coli and used to functionalize poly(lactic acid) nanoparticle surface is transcriptionally active in cellulo. Protein Expr Purif. 2015 Sep;113:94-101. doi: 10.1016/j.pep.2015.05.009

82. Lehner T and Wang Y. 2013. The role of stress-induced activation of HSP70 in dendritic cells, CD4+ T cell, memory and adjuvanticity. Chapter in book entitled Moonlighting Cell Stress Proteins in Microbial Infections, Heat Shock Proteins. Ed. B Henderson. Springer Science.

83. Lehner T and Wang Y. 2013. The potential mechanism of HSP70-derived stimulating peptide epitope in autoimmune Vitiligo. Sci. Trans. Med. (letter) 5:174.

84. Lemoine S, et al Dectin-1 co-activation of neonatal DCs corrects TLR-dependent TH1 deficiency. J Allerg Clin Immunol. 2015, doi:10.1016/j.jaci.2015.02.030

85. Lewis DJM, et al 2013. The effect of vaginal immunization in women with HIVgp140 and HSP70 on HIV-1 replication, innate and T cell adaptive immunity. J.Virol. 9 July 2014 , doi:10.1128/JVI.01621-14

86. Lindenstrøm T, Knudsen NP, Agger EM, Andersen, P., Control of Chronic Mycobacterium tuberculosis Infection by CD4 KLRG1- IL-2-Secreting Central Memory Cells.P.J Immunol. 2013 Jun 15;190(12):6311-9. doi: 10.4049/jimmunol.1300248

87. Maertzdorf J et al, Molecular signatures for vaccine development Vaccine 2015 Apr 6. pii: S0264-410X(15)00394-1. doi: 10.1016/j.vaccine.2015.03.075.

88. Maertzdorf, J et al. Common Patterns and disease-related signatures in tuberculosis and sarcoidosis. PNAS, 2012 May 15;109(20):7853-8. doi: 10.1073/pnas.1121072109

89. Maertzdorf, J et al. Enabling biomarkers for tuberculosis control .The International Journal of Tuberculosis and Lung Disease. 2012. 16:1140-1148

90. Maertzdorf, J., S. H.E. Kaufmann, J. Weiner III: Toward a unified biosignature for tuberculosis. Cold Spring Harb Perspect Med, doi: 10.1101/cshperspect.a018531. 4(6): a018531 (2014)

91. Mantovani A and M Locati Tumor-Associated Macrophages as a Paradigm of Macrophage Plasticity, Diversity, and Polarization: Lessons and Open Questions Arterioscler Thromb Vasc Biol 2013;33:1478-1483 doi:10.1161/ATVBAHA.113.300168

92. Mantovani A, etal. The long pentraxin PTX3: a paradigm for humoral pattern recognition molecules. Ann N Y Acad Sci. 2013 May doi: 10.1111/nyas.12043

93. Mastelic Gavillet B, et al MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus Germinal Center Responses in Adult and Early Life. J Immunol. 2015 May 15;194(10):4836-45. doi: 10.4049/jimmunol.1402071. Epub 2015 Apr 13

94. McElhaney J.E., Coler R.N., Baldwin S.L., Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults, Expert Review Vaccines 12(7), 759-766(2013)

95. Michelini Z, et al Murine granulocyte 1 macrophage colony stimulating factor expressed from a bicistronic SIV-based Integrase defective lentiviral vector does not enhance T-cell responses in mice. Viral Immunology 27:512-520, 2014. doi: 10.1089/vim.2014.0062.

96. Mihret, A., et al Combination of gene expression patterns in whole blood discriminate between tuberculosis infection states. BMC Infect. Dis. 14:257. doi: 10.1186/1471-2334-14-257 (2014)

Page 13

97. Negri DR, et al. Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines. Retrovirology. 2012;9:69 2012 doi: 10.1186/1742-4690-9-69

98. Nouailles G, et al CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis. J Clin Invest. 2014 Mar 3;124(3):1268-82. doi: 10.1172/JCI72030

99. Olafsdottir T, Lindqvist M, Harandi AM. Molecular signatures of vaccine adjuvants. Vaccine. 2015 May 16. pii: S0264-410X(15)00596-4. doi: 10.1016/j.vaccine.2015.04.099.

100. Olsen AW et al, Protection Against Chlamydia trachomatis Infection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein J Infect Dis.2015 Mar 6. pii: jiv137 [Epub ahead of print].

101. Olsen AW, Andersen P, Follmann F. Characterization of protective immune responses promoted by human antigen targets in a urogenial Chlamydia trachomatis mouse model. Vaccine 32(6): 685-692, 2014

102. Ottenhoff T H.M.and Kaufmann S.H.E State of the art in vaccine development against TB European Respiratory Society Monograph, Vol. 58. 2012. P.59-71 Published online November 29, 2012 doi:10.1183/1025448x.10015912

103. Ottenhoff TH et al. Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PLoS One. 2012;7(9):e45839. doi: 10.1371/journal.pone.0045839

104. Ottenhoff TH. New pathways of protective and pathological host defence to mycobacteria. Trends Microbiol. 2012 Sep;20(9):419-28. doi: 10.1016/j.tim.2012.06.00

105. Ottenhoff, T. H. M The knowns and unknowns of the immunopathogenesis of tuberculosis [State of the art] The International Journal of Tuberculosis and Lung Disease, Volume 16,Number 11, 1 November 2012 , pp. 1424-1432 doi.org/10.5588/ijtld.12.0479

106. Pappas L et al, Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature.2014 Dec 18;516(7531):418-22. doi: 10.1038/nature13764. Epub 2014 Oct 5.

107. Pavot V, Rochereau N, Lawrence P, Girard MP, Genin C, Verrier B, Paul S et al. Recent progress in HIV vaccines inducing mucosal immune responses AIDS. 2014 Jul 31;28(12):1701-18 2. doi:10.1097/QAD.0000000000000308

108. Pavot. V, Charlotte Primard, Bernard Verrier et al., Encapsulation of Nod1 and Nod2 receptor ligands into poly(lactic acid) nanoparticles potentiates their immune properties. Journal of Controlled Release 2013 Volume 167, Issue 1, 10 April 2013, p.60–67 doi.org/10.1016/j.jconrel.2013.01.015

109. Pettini E, et al. Vaginal immunization to elicit primary T-cell activation and dissemination PLoS One. 2013 Dec 5;8(12):e80545. doi: 10.1371/journal.pone.0080545.

110. Pritz T, et al. Plasma cell numbers decrease in bone marrow of old patients. Eur J Immunol. 2015 Mar;45(3):738-46 . doi: 10.1002/eji.201444878. .

111. Prota G, et al Peptide-specific population identified by MHC class II tetramers differentiates into several T helper subtypes upon immunization with CAF01 adjuvanted H56 tuberculosis vaccine formulation. Vaccine 2015, doi: 10.1016/j.vaccine.2015.09.024

112. Rappuoli R, Medaglini D. Big Science for Vaccine Development. Vaccine. 2014 Jun 25. pii: S0264-410X(14)00872-X. doi: 10.1016/j Vaccine.2014.06.071.

Page 14

113. Rappuoli R, Pizza M, Del Giudice G, De Gregorio E. Vaccines, new opportunities for a new society. Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12288-93. doi: 10.1073/pnas.1402981111

114. Rappuoli, R, Medaglini D. ADITEC: Joining Forces for Next-Generation Vaccines. Science Translational Medicine 2012 Apr 4;4(128):128cm4. doi: 10.1126/scitranslmed.3003826

115. Rasid O, et al Enhanced inflammatory potential of CD4+ T cells that lack proteasome immunosubunit expression in a T-cell transfer-based colitis model. PlosOne 2014 9(4):e95378 doi: 10.1371/journal.pone.0095378.

116. Richard M, et al. Low Virulence and Lack of Airborne Transmission of the Dutch Highly Pathogenic Avian Influenza Virus H5N8 in Ferrets. (2015) PLoS ONE 10(6): e0129827. doi:10.1371/journal.pone.0129827

117. Ronacher K Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS anddiabetes mellitus Immunol Rev. 2015 Mar;264(1):121-37. doi: 10.1111/imr.12257.

118. Rossi A, et al. Optimization of mucosal responses after intramuscular immunization with integrase defective lentiviral vector. PLoS One. Sep 11;9(9):e107377, 2014. Doi:10.1371/journal.pone.0107377

119. Russell RF, et al. The partial attenuation of Small Hydrophobic (SH) gene deleted RSV is associated with elevated IL-1β responses. J. Virol. 89: 8974-81.2015 doi: 10.1128/JVI.01070-15

120. Saiga H, et al. The Recombinant BCG ΔureC::hly Vaccine Targets the AIM2 Inflammasome to Induce Autophagy and Inflammation. J Infect Dis. 2014 Dec 11. pii: jiu675

121. Saletti, G., et al, C., Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood. Nature Protocols 2013 Jun;8(6):1073-87. doi: 10.1038/nprot.2013.058

122. Schiraldi M et al,. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4 J Exp Med. 2012 Mar 12; 209(3):551-63. doi: 10.1084/jem.20111739

123. Sloot R, et al. Biomarkers can identify pulmonary tuberculosis in HIV-infected drug users months prior to clinical diagnosis. EBioMedicine, in press doi: 10.1016/j.ebiom.2014.12.001.

124. Spensieri F, et al. Human circulating influenza-CD4+ ICOS1+IL-21+ T cells expand after vaccination, exert helper function, and predict antibody responses. Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14330-5. doi: 10.1073/pnas.1311998110

125. Tientcheu LD, et al. Differential transcriptomic and metabolic profiles of M. africanum- and M. tuberculosis-infected patients after, but not before, drug treatment. Genes Immun. 2015 Jun 4. doi: 10.1038/gene.2015.21.

126. Tregoning J, Kinnear E Using Plasmids as DNA Vaccines for Infectious Diseases Microbiolspec November 2014 vol. 2 no. 6 doi:10.1128/microbiolspec.PLAS-0028-2014

127. van den Brand JM,et al Comparision of.temporal and spatial dynamics of seasonal H3N2, pandemic H1N1 and highly-pathogenic avian H5N1 virus infections in ferrets. PLoS One.2012;7(8):e42343. doi:10.1371/journal.pone.0042343

128. van der Vaart M et al DRAM1 links pathogen recognition via TLR-MYD88 to autophagic defense against tuberculosis. Cell Host Microbe. 2014 Jun 11;15(6):753-67. doi: 10.1016/j.chom.2014.05.005.

Page 15

129. van Laarhoven Arjan, et al Low Induction of Proinflammatory Cytokines Paral van Soolingen lels Evolutionary Success of Modern Strains within the Mycobacterium tuberculosis Beijing Genotype Infect. Immun. October 2013 81:10 3750-3756; published ahead of print 29 July 2013, doi.org/10.1128/IAI.00282-13.

130. van Meijgaarden KE, et al. Human CD8+ T-cells recognizing peptides from Mycobacterium tuberculosis (Mtb) presented by HLA-E have an unorthodox Th2-like, multifunctional, Mtb inhibitory phenotype and represent a novel human T-cell subset. PLoS Pathogens, Mar 24;11(3):e1004671. doi: 10.1371/journal.ppat.1004671 (2015) .

131. van Ulsen P, et al. Type V secretion: from biogenesis to biotechnology. Biochim Biophys Acta. 2014 Aug;1843(8):1592-611. doi: 10.1016/j.bbamcr.2013.11.006

132. Venereau E et al, Uguccioni, M. Mutually exclusive redox forms of HMGB1 promote cell recruitment on proinflammatory cytokine release. J Exp Med. 2012 Aug 27;209(9):1519-28. doi: 10.1084/jem.20120189

133. Venereau E, Schiraldi, M., Uguccioni, M., Bianchi, ME., HMGB1 and leukocyte migration during trauma and sterile inflammation. Molecular Immunology 2013. Aug;55(1):76-82. doi:10.1016/j.molimm.2012.10.037

134. Vogelzang A, et al. Central Memory CD4+ T Cells Are Responsible for the Recombinant Bacillus Calmette-Guérin ΔureC::hly Vaccine's Superior Protection Against Tuberculosis. J Infect Dis. 2014 Jun 18. pii: jiu347.

135. Vono M, et al. The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination. Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21095-100. doi: 10.1073/pnas.1319784110

136. Walzl G Clinical Immunology and Multiplex Biomarkers of Human Tuberculosis Cold Spring Harbor Perspect Med.2014 Dec 4;5(4). pii: a018515. doi: 10.1101/cshperspect.a018515.

137. Wang Y et al. The Role of Innate APOBEC3G and Adaptive AID Immune Responses in HLA-HIV/SIV Immunized SHIV Infected Macaques. PlosOne. 2012; 7(4): e34433 doi: 10.1371/journal.pone.0034433

138. Wang Y, et al .Stress activated DC induce dual IL-elicit CD4+ memory T cells and IFN stimulated genes J Biol Chem. 2015 Apr 23 doi:10.1074/jbc.M115.645754.

139. Wang Yet al A comparative study of stress-mediated immunological functions with the adjuvanticity of alum. J Biol Chem. 2012 May 18;287(21):17152-60. doi: 10.1074/jbc.M112.347179

140. Wegmann F. et al. Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens. Nat Biotechnol. 2012 Sep;30(9):883-8

141. Weinberger B, et al. The stimulatory effect of the TLR4-mediated adjuvant glucopyranosyl lipid A is well preserved in old age. Biogerontology. 2015 May 9. [Epub ahead of print] PubMed PMID: 5957253.

142. Weinberger Bet al. Recall Responses to Tetanus and Diphtheria Vaccination Are Frequently Insufficient in Elderly Persons. PlosOne. 8(12): e82967, 2013

143. Weiner J 3rd, Kaufmann SH. Recent advances towards tuberculosis control: vaccines and biomarkers. J Intern Med. 2014 May;275(5):467-80. doi: 10.1111/joim.12212.

Page 16

144. Weiner, J, J. Maertzdorf, S.H.E. Kaufmann: The dual role of biomarkers for understanding basic principles and devising novel intervention strategies in tuberculosis. Ann. N.Y. Acad. Sci. 1283: 22-29. 2013

145. Wilson GJ, et al The C-type lectin receptor CLECSF8/CLEC4Dis a keycomponent of anti-mycobacterial immunity. Cell Host & Microbe 17, 252–259 (2015). doi: 10.1016/j.chom.2015.01.004.

146. Zak DE, Aderem A. Systems integration of innate and adaptive immunity. Vaccine. (2015). Sep 29;33(40):5241-8. doi: 10.1016/j.vaccine.2015.05.098

147. Zhang X. et al CD4 T Cells with Effector Memory Phenotype and Function Develop in the Sterile Environment of the Fetus Sci Transl Med 6, 238ra72 (2014); DOI: 10.1126/scitranslmed.3008.

148. Zhang Xet al. Plasmacytoid DC engagement by Flu vaccine as a surrogate strategy for driving Th1 responses in human neonatal settings. J. Infect Dis. 2014. doi: 10.1093/infdis/jiu103.